IMMUNE - STRONG BUY - 500 Beiträge pro Seite

[Klausle]

PR NEWSWIRE) Gilead Sciences, ImmunoGen, Immune Response Among 125 Public an
Gilead Sciences, ImmunoGen, Immune Response Among 125 Public and Private
Companies Streamed Live by InformedInvestors.com at Boston BIO 2000 Conference

ROSEVILLE, Calif., March 27 /PRNewswire/ -- InformedInvestors.com will
audiostream all company presentations from the International Investors
& Partnering Forum, a segment of the Biotechnology Industry Organization`s
(BIO) annual conference and exhibition in Boston starting Monday, March 27th
and running through Wednesday, March 29th.
To tune in free and live beginning March 27 at 8:00 a.m. EST, visit
www.informedinvestors.com and click on "Listen to BIO 2000." Presentations
will also be archived for replay.
"Our `straight-from-the-source` in-depth insights on the biotechnology and
technology sectors is our trademark, and we`re truly excited about
participating in the BIO conference as a streaming sponsor," said Tim Quast,
InformedInvestors.com President and COO. "It`s a chance for biotech investors
everywhere to get a firm sense of the direction and drivers of the biotech
industry, both at the public and private levels."
Gilead Sciences, Inc. (Nasdaq: GILD), ImmunoGen, Inc. (Nasdaq: IMGN),
StressGen Biotechnologies Corp. (Toronto: SSB), and
Immune Response Corp. (Nasdaq: IMNR) and privately-held Myogen, Inc.
(www.myogen.com) are among scores of presenting companies kicking off the
International Investors & Partnering Forum Monday. Each presentation is a
20-minute "state-of-the-company" snapshot. Companies present in two
simultaneous tracks.
Myogen is a private, venture-backed company that develops drugs to treat
heart failure. Myogen`s first product, Perfan I.V., an intravenous formulation
of enoximone, is sold in Europe as a treatment for hospitalized patients
suffering from advanced heart failure. Myogen will soon begin Phase III
clinical testing in the U.S. and Europe of an orally delivered formulation of
enoximone for treating heart failure. Myogen in-licensed worldwide rights for
enoximone from Hoechst Marion Roussel in 1998.
The Biotechnology Industry Organization (BIO) represents biotechnology
companies, academic institutions, state biotechnology centers and related
organizations throughout the United States and in many other countries. The
members of BIO apply biological knowledge and techniques to develop products
and services for use in health care, agriculture, environmental remediation,
and other fields. See details at www.bio.org.
InformedInvestors.com is the leading producer of online and offline
industry-specific investment conferences for individual investors and offers a
growing stable of resources for in-depth sector-analysis, including the weekly
biotech-sector radio show, "BioTalk."

SOURCE InformedInvestors.com
-0- 03/27/2000
/CONTACT: Steve Chanecka of InformedInvestors.com, 916-780-6100, or
800-992-4683/
/Web site: http://www.informedinvestors.com/
(GILD IMGN IMNR SSB.)

CO: InformedInvestors.com; Gilead Sciences, Inc.; ImmunoGen, Inc.; Immune
Response Corp.; StressGen Biotechnologies Corp.; Myogen, Inc.
ST: California, Massachusetts
IN: FIN MLM BIO
SU:


*** end of story ***

[Klausle]

Und weil es so schön ist - noch eine News:


(PR NEWSWIRE) The Immune Response Corporation Announces Progress in the Ident
The Immune Response Corporation Announces Progress in the Identification Of
Genes Modulated During Spinal Cord Injury and Peripheral Nerve Regeneration

Company Scientists Use Functional Genomics Coupled With in Vivo Models
To Identify Genes Involved in Spinal Cord Injury
And Peripheral Nerve Regeneration

CARLSBAD, Calif., March 27 /PRNewswire/ -- The Immune Response Corporation
(Nasdaq: IMNR) announced today that it has made progress in identifying the
gene expression patterns following anti-inflammatory treatment for spinal cord
injury and the genetic basis underlying peripheral nerve regeneration. The
results from microarray (gene chip) studies reported on March 23, 2000, at
the, Washington, D.C., may provide the basis for developing new treatments for
acute and chronic spinal cord injury.
"Methylprednisolone, an anti-inflammatory steroid, has been the standard
of care for patients with acute spinal cord injury. We are now beginning to
understand the genetic basis for its neuroprotective effect," said Dr. Adrian
A. Cameron, Research Scientist, The Immune Response Corporation. "We have
identified several hundred genes apparently involved in the injured spinal
cord`s response to methylprednisolone treatment, which may provide a basis for
developing more specific and potent anti-inflammatory agents and new
strategies for the treatment of acute spinal cord injury."
The latest "gene chip" technologies were employed to compare the changes
in gene expression or activity in spinal cord-injured rats subsequently
treated either with methylprednisolone or saline as a control. Gene chips, or
gene expression microarrays, are a genomics tool that contains thousands of
human genes arranged on a glass chip and can be used to catalogue gene
activity in different nerve tissues or different experimental situations. By
comparing gene expression profiles between the two groups of experimental
rats, the scientists determined which genes were differentially turned on or
off as a result of methylprednisolone treatment.
The results suggest that methylprednisolone administration appears to
cause suppression of gene activity in the injured spinal cord, particularly of
genes that promote inflammation and proliferation of cell types that may
prohibit regrowth of damaged nerve tissue. A small percentage of genes were
observed to increase in activity, and these were identified as genes encoding
antioxidants, growth factors, and matrix proteins known to have
neuroprotective effects.
"Such patterns of gene activity resulting from methylprednisolone
treatment may underlie this drug`s ability to suppress the immediate
inflammation that occurs following trauma that is responsible for `secondary
damage` to the spinal cord tissues," said Dr. Cameron.
Data were also reported on experiments that examined the genetic basis of
peripheral nerve regeneration. Gene expression profiles were obtained during
the regeneration of experimentally injured dorsal root ganglia, masses of cell
bodies located in the peripheral nervous system (PNS), and also of activated
Schwann cells, which are specialized cells of the PNS that play a supportive
role in nerve impulse transmission.
"In contrast to the central nervous system (the brain and spinal cord),
the PNS can survive trauma and regrow damaged neurons to restore motor
function. The PNS is therefore an important model to study in devising
strategies for the treatment of chronic spinal cord injury. To this end, we
have identified a whole cluster of genes that apparently can be turned off or
on at different points during the `regeneration cycle` of neurons in the PNS,"
said Dr. Cameron. "Our next steps are to determine which of these genes, if
any, play a causal role in nerve regeneration and could potentially serve as
candidates for drug targets or gene therapy to treat chronic spinal cord
injury, in which neuron regeneration may be necessary for functional
restoration."
The Immune Response Corporation is a biopharmaceutical company based in
Carlsbad, California, developing immune-based therapies to induce specific
T-cell responses for the treatment of HIV and autoimmune diseases. In
addition, the Company is working on cancer vaccines and gene therapy.

NOTE: News releases are available through PR Newswire Company News
On-Call fax service. For a menu of available news releases or to retrieve a
specific release made by The Immune Response Corporation, please call
800-758-5804, extension 434675. Please retain these numbers for future
reference. Company information can also be located on the Internet Web Site:
http://www.imnr.com.

This news release contains forward-looking statements. Actual results
could vary materially from those expected due to a variety of risk factors,
including, but not limited to, whether clinical trials will be initiated,
whether if initiated clinical trials will be successfully concluded and
whether any potential product(s) will be approved for marketing or be
successfully commercialized. Those factors are discussed more thoroughly in
The Immune Response Corporation`s SEC filings, including but not limited to
its report on Form 10-K for the year ended December 31, 1998 and subsequent
Forms 10-Q. The Company undertakes no obligation to publicly release the
result of any revisions to these forward-looking statements which may be made
to reflect events or circumstances after the date hereof or to reflect the
occurrence of unanticipated events.

SOURCE The Immune Response Corporation
-0- 03/27/2000
/CONTACT: C. Richard Ill, Ph.D., Senior Director of Molecular and
Cellular Biology of The Immune Response Corporation, 760-431-7080/
/Company News On-Call: http://www.prnewswire.com/comp/434675.html or fax,
800-758-5804, ext. 434675/
/Web site: http://www.imnr.com/
(IMNR)

CO: Immune Response Corporation; American Society for Experimental
Neurotherapeutics
ST: California, District of Columbia
IN: MTC BIO
SU:

*** end of story ***